What is Allevi?
Allevi is a prominent entity in the field of 3D bioprinting technology. The company has historically offered a comprehensive suite of bioprinters and bioinks designed to serve researchers across tissue engineering, organ-on-a-chip applications, and pharmaceutical development. Their product line, which included models like the Allevi 1, 2, and 3, was recognized for its versatility, precision, and user-friendly design, enabling the printing of diverse cell lines and bioinks. Allevi's technological solutions have been instrumental in advancing drug discovery, regenerative medicine, and disease modeling, positioning them as a key partner within the bioprinting research community. Although the production of their bioprinters ceased in 2023, the company continues to support bioprinting research through its software and material offerings.
How much funding has Allevi raised?
Allevi has raised a total of $397K across 2 funding rounds:
Debt
$150K
Debt
$247K
Debt (2020): $150K with participation from PPP
Debt (2021): $247K led by PPP
Key Investors in Allevi
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Allevi?
With a history of substantial funding, Allevi's strategic investments indicate a focus on solidifying its market presence and potentially expanding its technological capabilities or service offerings within the bioprinting ecosystem. The company's transition from hardware production to software and materials suggests a strategic pivot towards supporting ongoing research and development in regenerative medicine and drug discovery, leveraging its established expertise and brand recognition.
See full Allevi company page
